Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
Adagene, airborne, ample, analogy, anesthesiologist, antigen, app, authentic, authoritative, bandwidth, belzutifan, Biden, bioavailable, bioconjugation, biosafety, Bioscience, bispecific, CANTATA, capsule, capture, career, Catalent, celebrate, chance, chemoembolization, Chugai, closure, CMC, comfortable, conference, constant, contact, contributor, County, covalent, COVID, CPRA, culture, curative, curatively, cytoreductive, default, defaulted, Delinquent, dental, deploy, deployed, devise, die, disability, discrimination, disinfection, distancing, downturn, economy, empowered, ENA, exacerbate, exacerbated, exceeding, Excellence, excelling, extra, familiar, feel, Ffactor, flexibility, fulvestrant, fume, gender, genomic, GLP, gravity, greatest, hand, home, hub, hygiene, impressive, infection, installing, intentionally, interface, interfere, interference, interview, job, lab, leadership, live, machinery, marital, masked, mental, MER, mile, mobile, mortality, NBE, negligent, nurse, nurture, Official, onboarding, Ono, OPDIVO, Optum, orientation, pairing, pandemic, PCR, Peloton, pharmacokinetic, PharmD, phishing, pilot, Poorly, posed, prednisone, proportional, proud, race, Redwood, religion, remote, remotely, retrained, RTOR, SAFEbody, SAFEbodyTM, sanitizer, sanitizing, Scherer, sexual, shelter, sizable, SMARTag, staffing, steadily, strive, stronger, surge, suspension, SWOG, symptom, synergistic, tablet, TECENTRIQ, teleaglenastat, temporarily, thought, today, tracing, transarterial, transcriptional, tuition, tying, unblind, undergone, undiscounted, unemployment, unfavorable, unlawful, vaccinated, ventilation, veteran, virtual, vision, voucher, workforce, workspace
Removed:
add, aim, alongside, Amgen, antiangiogenic, applying, AstraZeneca, avelumab, AVEO, backlog, built, Cadillac, call, capitalize, carried, choice, commercialized, communicate, comparison, conceal, concentrating, conditioned, consultation, continuity, crizotinib, deficit, dictate, disaster, distraction, diversion, doubled, doublet, doubtful, earthquake, educating, England, entirety, espionage, evaluable, favoring, Francisco, frequency, fundamental, glesatinib, hacker, hamper, harder, image, inappropriate, incorrect, inferred, inform, interpretation, judge, judged, Lancet, malpractice, mandate, match, media, motive, mutant, navigate, nonstatutory, obligated, occasion, occurrence, oncologic, packaging, panitumumab, parallel, partial, percent, physical, ponatinib, poor, PR, preparing, productive, propriety, prosecute, prosecution, PRs, publicly, qui, radiology, reinvesting, relinquish, renew, repeat, request, resolve, run, sabotage, San, savolitinib, SD, seasonality, selecting, session, smaller, stable, stipulated, stopped, subgroup, successive, surveillance, sustain, tam, tangible, terrorism, theft, tivozanib, transition, tremelimumab, trend, UK, unavailable, uncollectible, unexpected, unused, validation, vested, violated, wrongfully
Filing tables
Filing exhibits
Related press release
Associated EXEL transcripts
EXEL similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 333-241667, 333-226493, 333-223225, 333-218236, 333-214766, 333-212866, 333-209824, 333-203758, 333-196761, 333-176674, 333-165389, 333-159280, 333-157825, 333-149834, 333-147063, 333-133237, 333-124536, 333-113472, 333-102770, 333-82724, 333-82722, 333-57026 and 333-35862) of Exelixis, Inc. and the Registration Statement (Form S-3 No. 333-205397) and related Prospectus of Exelixis, Inc. of our reports dated February 10, 2021, with respect to the consolidated financial statements of Exelixis, Inc. and the effectiveness of internal control over financial reporting of Exelixis, Inc., included in this Annual Report (Form 10-K) for the year ended January 1, 2021.
/s/ Ernst & Young LLP
Redwood City, California
February 10, 2021